Lipodystrophy
79
5
7
56
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Published Results
15 trials with published results (19%)
Research Maturity
56 completed trials (71% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.3%
1 terminated out of 79 trials
98.2%
+11.7% vs benchmark
20%
16 trials in Phase 3/4
27%
15 of 56 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 56 completed trials
Clinical Trials (79)
Effects of Meal Macronutrients on Postprandial Lipids
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)
Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling
The Cleveland Cardiometabolic Cohort
Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance
Susceptibility to Infectious Diseases in obEsity: an endocRine trAnslational socioLogic Evaluation, "SIDERALE"
Carotid Doppler Peak Velocity Variation in Liposuction Fluid Management
Low Energy Diet and Familial Partial Lipodystrophy
Assess the Possibility of Diagnosing Diabetes and Rediabetes Following Oral Induced Hyperglycemia in Patients With Dunnigan's Partial Familial Lipodystrophy by Replacing 75 g of Glucose With a Standardized Carbohydrate Breakfast and Continuous Interstitial Monitoring Glucose)
Performance and Safety of the Lipo-transfer Cannulas in Patients Underlying Lipofilling Treatment
Intraoperative Fluid Management of Liposuction , Cardiometry Versus Rohrich Formula
Impact of Lipodystrophy on the Inflammatory State of Non-diabetic Dunnigan Reunion Island Subjects
Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan's Lipodystrophy
Evaluating the Performance and Safety of the Medical Device Plenhyage® in the Treatment of Dermal Tissue Defects
Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects
Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects
Evaluating the Performance and Safety of the Medical Device Janesse in the Treatment of Facial Dermal Tissue Defects